arrow
C

Clemens-Martin Wendtner

klinikum munchen-schwabing
H指数:65
被引数:2.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The HLH-Risk-Calculator is a machine learning-based tool to predict course & mortality of secondary hemophagocytic lymphohistiocytosis

HLH风险计算器是一种基于机器学习的工具,用于预测继发性噬血细胞性淋巴组织细胞增多症的病程和死亡率

2026-06-300
OAAI
Risk factors for severe post-COVID condition in children, adolescents, and young adults

儿童、青少年和年轻成年人严重新冠后遗症的风险因素

2026-05-040
OAAI
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia

Al-Sawaf, O.; Stumpf, J.; Zhang, C.; Simon, F.; Bosch, F.; Feyzi, E.; Ghia, P.; Gregor, M.; Kater, A.P.; Lindström, V.; 等. 固定疗程与持续治疗在慢性淋巴细胞白血病中的应用比较. N. Engl. J. Med. 2025, 393, 24. [Google Scholar] [CrossRef]

2025-12-018
PRE
The role of trephine bone marrow biopsies in the era of measurable residual disease-Results from the CLL10 trial of the German CLL Study Group (GCLLSG)
2024-07-240
OAAI
Remdesivir for Treatment of Coronavirus Disease 2019 Requiring Oxygen Support: A Cross-Study Comparison From 2 Large, Open-Label Studies
2024-06-260
PRE
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial
2024-04-050
OAAI
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial
2023-12-0914
OAAI
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia
2023-05-11124
PRE
Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
LEUKEMIA
IF13.4
2022-06-254
OAAI
Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
2022-06-012
OAAI
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
2022-04-0143
OAAI
Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination
2021-06-2367
OAAI